866-997-4948(US-Canada Toll Free)

Abraxane (Non-Small Cell Lung Cancer) -Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jun 2013

Category :

Cancer

No. of Pages : 54 Pages


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Celgenes Abraxane (nab-paclitaxel), in combination with carboplatin, is approved by the FDA for first-line use in advanced NSCLC patients in the US. Abraxane was approved for use in NSCLC in Japan in February 2013 and is marketed in Japan by Taiho Pharmaceuticals. At the time of this publication, Celgene had not announced that it had submitted filings seeking marketing approval for NSCLC to the EMA. Abraxane was approved for metastatic breast cancer in the US in 2005, the EU in 2008, and Japan in 2010.

Scope

  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Abraxane including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Abraxane for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Abraxane performance
  • Obtain sales forecast for Abraxane from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology and Histology 12
3.1.3 NSCLC Biomarkers 13
3.1.4 Quality of Life 14
3.2 Symptoms 15

4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 19
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29

6 Abraxane (nab-paclitaxel) 32
6.1 Overview 32
6.2 Efficacy 33
6.3 Safety 34
6.4 SWOT Analysis 35
6.5 Forecast 35

7 Appendix 37
7.1 Bibliography 37
7.2 Abbreviations 41
7.3 Methodology 44
7.4 Forecasting Methodology 44
7.4.1 Number of NSCLC Patients Currently Seeking Treatment 44
7.4.2 Percent Drug-treated Patients 45
7.4.3 General Pricing Assumptions 45
7.4.4 Individual Drug Assumptions 48
7.4.5 Generic Erosion 48
7.5 Physicians and Specialists Included in This Study 49
7.6 Survey of Prescribing Physicians 50
7.7 About the Authors 51
7.7.1 Author 51
7.7.2 Epidemiologist 51
7.7.3 Global Head of Healthcare 52
7.8 About GlobalData 53
7.9 Disclaimer 53

List of Table


Table 1: Symptoms of Disease NSCLC 16
Table 2: Treatment Guidelines for NSCLC 18
Table 3: Stage Definitions for NSCLC 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27
Table 5: Leading Treatments for NSCLC 31
Table 6: Product Profile Abraxane (nab-paclitaxel) 33
Table 7: Abraxane SWOT Analysis, 2013 35
Table 8: Global Sales Forecasts ($m) for Abraxane, 2012-2022 36
Table 9: Five Year Prevalence 45
Table 10: Physicians Surveyed by Country 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *